Cuprina Holdings (Cayman) LTD is a Singapore based biomedical and biotechnology company. It focuses on the development and commercialization of innovative products for chronic wound management and the health and beauty sector. The company’s lead product is the MEDIFLY maggot debridement therapy, a sterile blowfly larvae bio dressing used in hospitals and clinics. In addition to its commercialized wound care line, Cuprina maintains a pipeline that includes collagen dressings derived from bullfrog skin, iodine based topical antiseptics, and medical leech therapy. It also operates a cosmeceuticals business that offers a hydrating balm, a muscle energy cream, and a pain relief patch. All research and development activities are conducted through collaborations with Nanyang Technological University and joint ventures with partners such as Aiodine Laboratory. The firm aims to address each stage of the wound healing process while leveraging sustainable sourcing of raw materials from waste streams.

Revenue is generated principally from the sale of MEDIFLY products to public and private hospitals and clinics. In 2024 the MEDIFLY line accounted for 71.2 percent of total revenue and in 2025 it represented 88.6 percent of revenue. The cosmeceutical portfolio comprising the MEND Skin Restoration Balm, the ENDURE Muscle Energy Cream, and the Activ Labs Cool Relief Muscle Patch contributes additional sales through retailers, gyms, and online platforms such as Shopee. Revenue from the cosmeceutical business is earned via direct to consumer channels and through third party distributors. Although the collagen dressings, iodine based antiseptics, and leech therapy products are still in development the company anticipates they will generate future revenue once regulatory approvals are obtained. For the years ended December 31 2023 2024 and 2025 revenue amounted to S$100,773 S$48,321 and S$49,894 respectively. Net loss for the same periods was S$1,119,555 S$1,560,535 and S$4,673,447.

Cuprina Holdings (Cayman) LTD operates in a competitive global chronic wound care market that includes large multinational corporations. Key competitors are Smith & Nephew plc, ConvaTec Group plc, Mölnlycke Health Care AB, 3M, and Integra Urgo Group. The company differentiates itself through a unique product pipeline that combines maggot debridement therapy, bullfrog collagen based dressings, iodine based antiseptics, and medical leech therapy. Cuprina benefits from an exclusive license with Nanyang Technological University to produce collagen from bullfrog skin which offers superior biocompatibility and thermal stability compared to bovine or marine sources. Its joint venture with Aiodine Laboratory provides worldwide rights to commercialize iodine based wound care and topical antiseptic products. The firm emphasizes sustainability by breeding maggots and leeches in house and by valorizing waste streams such as discarded bullfrog skins. These factors give Cuprina a cost advantage and appeal to environmentally conscious healthcare providers. The underlying market is driven by an aging population rising diabetes rates and increasing prevalence of chronic wounds which together support long term growth prospects.

The company’s wound care products are sold primarily to major public and private hospitals and clinics in Singapore. Its cosmeceutical brands are distributed through retailers, gyms, and online platforms in Singapore, Malaysia, Australia, and other regions. Specific partnerships include the collaboration with Full Crimp Milk for the MEND Skin Restoration Balm, the agreement with Advanced Biotech for exclusive distribution of MEDIFLY in Hong Kong, and the joint venture with Aiodine for iodine based products. Although the firm does not disclose individual customer names it notes that its five largest customers accounted for approximately 65.7 percent of total revenue in 2025. The largest single customer contributed about 28.3 percent of revenue in the same year.